Fund Details
Overview
Investment portfolio
10rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Ability biologics | Jun 2024Participated | $18 MSeed | |
Domain Therapeutics | May 2022Participated | $41 MSeries A | |
DrugBank | Apr 2022Participated | $9 MSeed | |
Cascador Health | Mar 2022Participated | $4 MOther Equity | |
HypnoVR | Dec 2021Led | $5 MSeries A | |
Kaspard | Jul 2021Participated | $4 MOther Equity | |
Giiant Pharma | May 2021Participated | $11 MSeed | |
Classcraft | Mar 2021Participated | $4 MOther Equity | |
PharmaFluidics | Jan 2018Participated | $9 MOther Equity | |
Ovizio | Nov 2015Participated | $9 MOther Equity | |
Ability biologics | Jun 2024Participated | $18 MSeed | |
Domain Therapeutics | May 2022Participated | $41 MSeries A | |
DrugBank | Apr 2022Participated | $9 MSeed | |
Cascador Health | Mar 2022Participated | $4 MOther Equity | |
HypnoVR | Dec 2021Led | $5 MSeries A | |
Kaspard | Jul 2021Participated | $4 MOther Equity | |
Giiant Pharma | May 2021Participated | $11 MSeed | |
Classcraft | Mar 2021Participated | $4 MOther Equity | |
PharmaFluidics | Jan 2018Participated | $9 MOther Equity | |
Ovizio | Nov 2015Participated | $9 MOther Equity |
10 Items
10
Items
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 3 |
| Series A | 1 | 1 |
| Other Equity | 0 | 5 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Nov '15 | 1 |
| Dec '15 | 0 |
| Jan '16 | 0 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 0 |
| May '16 | 0 |
| Jun '16 | 0 |
| Jul '16 | 0 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 0 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 1 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 0 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 1 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 1 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 1 |
| Apr '22 | 1 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 8 |
| Networks, Cloud & Communication | 2 |
| AR/VR | 2 |
| Education & Workforce | 1 |
| Enterprise Software | 1 |
| Government & Defense | 1 |
| Cybersecurity & Privacy | 1 |
| AI & Machine Learning | 1 |
| Gaming & eSports | 1 |
| Data, Analytics & IT | 1 |
| Space & Frontier Tech | 1 |
| Social & Community Platforms | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 3 |
| $5M-$10M | 4 |
| $10M-$25M | 2 |
| $25M-$50M | 1 |
| $50M-$100M | 0 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 6 |
| Canada | 4 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Amplitude Ventures | 3 |
| Qbic | 3 |
| Brightspark Ventures | 2 |
| Fonds de solidarit FTQ | 2 |
| 3B Future Health Fund | 1 |
| Accelerate Fund III | 1 |
| adMare BioInnovations | 1 |
| Akiles | 1 |
| Alexandria Venture Investments | 1 |
| AmorChem | 1 |
| Amplify Capital | 1 |
| Anges Québec | 1 |
| Banque des Territoires | 1 |
| Bpifrance | 1 |
| Capital Grand Est | 1 |
| Charles River Laboratories | 1 |
| CTI Life Sciences Fund | 1 |
| finance&invest.brussels | 1 |
| Genesys Capital | 1 |
| HERAN Partners | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 1 | 10% |
| Participating | 9 | 90% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 1 | 100% |
Team
Olivier Belenger
Founder and Managing Partner
Théo Risopoulos
Principal
